Shanghai ZJ Bio-Tech Co (SHSE:688317) ROE %: -3.07% (As of Mar. 2026)


SHSE:688317 Shanghai ZJ Bio-Tech Co Ltd SHSE:688317
68 GF Score
Price ¥15.68
GF Value ¥9.94
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Shanghai ZJ Bio-Tech Co ROE %?

Shanghai ZJ Bio-Tech Co SHSE:688317 -4.33% 68 ROE % is -3.07% as of Mar. 2026. GuruFocus rates SHSE:688317 with a GF Score™ of 68/100 and a GF Value™ of ¥9.94 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Shanghai ZJ Bio-Tech Co ranks worse than 57.45% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Shanghai ZJ Bio-Tech Co's annualized net income for the quarter that ended in Mar. 2026 was ¥-102.0 Mil. Shanghai ZJ Bio-Tech Co's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ¥3,325.7 Mil. Therefore, Shanghai ZJ Bio-Tech Co's annualized ROE % for the quarter that ended in Mar. 2026 was -3.07%.

The historical rank and industry rank for Shanghai ZJ Bio-Tech Co's ROE % or its related term are showing as below:

SHSE:688317' s ROE % Range Over the Past 10 Years
Min: -3.42   Med: 11.29   Max: 91.62
Current: -1.29

During the past 13 years, Shanghai ZJ Bio-Tech Co's highest ROE % was 91.62%. The lowest was -3.42%. And the median was 11.29%.

SHSE:688317's ROE % is ranked worse than
57.45% of 799 companies
in the Medical Devices & Instruments industry
Industry Median: 2.42 vs SHSE:688317: -1.29

Shanghai ZJ Bio-Tech Co  (SHSE:688317) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-102.04/3325.723
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-102.04 / 101.676)*(101.676 / 3735.2635)*(3735.2635 / 3325.723)
=Net Margin %*Asset Turnover*Equity Multiplier
=-100.36 %*0.0272*1.1231
=ROA %*Equity Multiplier
=-2.73 %*1.1231
=-3.07 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-102.04/3325.723
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-102.04 / -95.588) * (-95.588 / -91.104) * (-91.104 / 101.676) * (101.676 / 3735.2635) * (3735.2635 / 3325.723)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0675 * 1.0492 * -89.6 % * 0.0272 * 1.1231
=-3.07 %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Shanghai ZJ Bio-Tech Co ROE % Related Terms


Shanghai ZJ Bio-Tech Co ROE % Historical Data

* Premium members only.

The historical data trend for Shanghai ZJ Bio-Tech Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai ZJ Bio-Tech Co ROE % Chart

Shanghai ZJ Bio-Tech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.68 18.94 -3.41 -3.42 -0.98

Shanghai ZJ Bio-Tech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.79 0.71 -2.28 -0.58 -3.07

SHSE:688317 vs ABT, SYK, MDT: ROE % Comparison

For the Medical Devices subindustry, Shanghai ZJ Bio-Tech Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai ZJ Bio-Tech Co ROE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shanghai ZJ Bio-Tech Co's ROE % distribution charts can be found below:

* The bar in red indicates where Shanghai ZJ Bio-Tech Co's ROE % falls into.


SHSE:688317
68GF Score
Shanghai ZJ Bio-Tech Co Ltd SHSE:688317
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai ZJ Bio-Tech Co ROE % Calculation

Shanghai ZJ Bio-Tech Co's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-34.298/( (3636.887+3348.849)/ 2 )
=-34.298/3492.868
=-0.98 %

Shanghai ZJ Bio-Tech Co's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=-102.04/( (3348.849+3302.597)/ 2 )
=-102.04/3325.723
=-3.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of -3.07% mean?
Shanghai ZJ Bio-Tech Co (SHSE:688317) has a ROE % of -3.07% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. According to the industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #459 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 57.4%.
Is Shanghai ZJ Bio-Tech Co's ROE % too high?
Shanghai ZJ Bio-Tech Co's current ROE % is -3.07%. Based on the distribution chart, Shanghai ZJ Bio-Tech Co ranks #459 out of 799 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Shanghai ZJ Bio-Tech Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai ZJ Bio-Tech Co's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #459 out of 799 companies for ROE %. This places Shanghai ZJ Bio-Tech Co in the lower half of its industry. The industry median ROE % is 2.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai ZJ Bio-Tech Co's current ROE % is -3.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai ZJ Bio-Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co (SHSE:688317) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥9.94, compared to a current price of ¥15.68 — trading 57.7% above its estimated fair value. The current ROE % is -3.07%. Shanghai ZJ Bio-Tech Co's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Shanghai ZJ Bio-Tech Co (SHSE:688317), the current ROE % is -3.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai ZJ Bio-Tech Co (SHSE:688317) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co stock appears to be overvalued. The current stock price of ¥15.68 is trading 57.7% above its estimated GF Value™ of ¥9.94. GuruFocus considers Shanghai ZJ Bio-Tech Co to be Significantly Overvalued.

Key valuation signals for SHSE:688317:

  • ROE %: -3.07%
  • GF Value™: ¥9.94 vs. price of ¥15.68 (57.7% above fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai ZJ Bio-Tech Co Business Description

Address No. 588 Xinjun Ring Road, Building 26, Pujiang Hi-Tech Park, Caohejing Development Zone, Shanghai, CHN
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.
68GF Score

Get the complete analysis for SHSE:688317

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.68
Price
¥9.94
GF Value